MIMEDX to Participate at Upcoming Investor Conferences

Rhea-AI Summary

Marietta, Ga. — MiMedx Group (Nasdaq: MDXG) announced its participation in upcoming virtual investor conferences. CEO Timothy R. Wright, CFO Peter M. Carlson, and CCO Rohit Kashyap will engage in fireside chats at the Credit Suisse 30th Annual Healthcare Conference on November 9, 2021, at 3:30 PM ET, and the Canaccord Genuity MedTech Forum on November 18, 2021, at 9:30 AM ET. Webcasts will be available via the company’s website. MiMedx specializes in regenerative medicine utilizing amniotic tissue for wound care and musculoskeletal conditions.

MARIETTA, Ga., Nov. 02, 2021 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), an industry leader in utilizing amniotic tissue as a platform for regenerative medicine, today announced that Timothy R. Wright, Chief Executive Officer, Peter M. Carlson, Chief Financial Officer, and Rohit Kashyap, Ph.D., Chief Commercial Officer, will be participating in the following virtual investor conferences:

• Credit Suisse 30^th Annual Healthcare Conference
  Fireside Chat: Tuesday, November 9, 2021 at 3:30 PM ET
  Webcast: Click here to access

• Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum
  Fireside Chat: Thursday, November 18, 2021 at 9:30 AM ET
  Webcast: Click here to access

Institutional investors interested in meeting with management may contact their respective Credit Suisse or Canaccord Genuity representative.

A webcast of both fireside chats will be available on the Events page of the Investors section of the Company’s website at www.mimedx.com or through the conference site by using the links above. A replay will be available on the Company’s website following the event.

About MIMEDX
MIMEDX is an industry leader in utilizing amniotic tissue as a platform for regenerative medicine, developing and distributing placental tissue allografts with patent-protected, proprietary processes for multiple sectors of healthcare. As a pioneer in placental biologics, we have both a base business, focused on addressing the needs of patients with acute and chronic non-healing wounds, and a promising late-stage pipeline targeted at decreasing pain and improving function for patients with degenerative musculoskeletal conditions. We derive our products from human placental tissues and process these tissues using our proprietary methods, including the PURION® process. We employ Current Good Tissue Practices, Current Good Manufacturing Practices, and terminal sterilization to produce our allografts. MIMEDX has supplied over two million allografts, through both direct and consignment shipments. For additional information, please visit www.MIMEDX.com.

Contacts:
Investors
Jack Howarth
404-360-5681
jhowarth@mimedx.com

Corporate Communications
Hilary Dixon
404-323-4779
hdixon@mimedx.com

FAQ

When is the Credit Suisse Annual Healthcare Conference for MiMedx (MDXG)?

The Credit Suisse 30th Annual Healthcare Conference featuring MiMedx will take place on November 9, 2021, at 3:30 PM ET.

What can investors expect from MiMedx's participation in the Canaccord Genuity Forum?

MiMedx will present at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum on November 18, 2021, at 9:30 AM ET.

How can I access the webcasts of MiMedx's investor conferences?

Webcasts can be accessed via links provided in the press release or on MiMedx's official website.

What is the focus of MiMedx Group's business?

MiMedx specializes in regenerative medicine using amniotic tissue to address non-healing wounds and musculoskeletal conditions.

What types of products does MiMedx offer?

MiMedx develops and distributes placental tissue allografts for various healthcare needs, particularly for chronic wounds and pain relief.